Companies in pre-clinical contractual research
Montreal Metro can pride itself for having some of the world leaders in the non-clinical contractual research established on its territory.
Some of the key players include:
Charles River Laboratories Preclinical Services (formerly CTBR)
www.criver.com/preclinical_services
President Global Preclinical Services: Nancy A. Gillett
1,500 employees
As one of the largest preclinical services company, Charles River Preclinical Services offers a highly technical and broad range of preclinical services in its Montreal facility. Services offered to the industry include discovery, toxicology, pathology, drug metabolism, pharmacokinetics and laboratory sciences.
CRL Preclinical Services in Montreal is the largest single preclinical facility in the world. It employs over 1,500 people and it can run all types of studies required by regulatory agencies such as the US FDA for the filing of a new drug.
LAB Research Inc. (TSX: LRI)
www.preclin.com/home.htm
President & CEO : Luc Mainville
450 employees
LAB Research, founded in 1998, is one of the few global organizations dedicated exclusively to preclinical services to be publicly traded on a major stock exchange. With its more than 400 clients, it is now a top 10 provider of in-vivo non-clinical services for the global pharmaceutical, biotechnology and agrochemical marketplaces with facilities in Canada, USA, Hungary and Denmark.
LAB Research delivers comprehensive services in all areas of preclinical drug development to its clients. Its services include general toxicology, minipig toxicology, safety pharmacology, genetic toxicology, immuno toxicology, ecotoxicology, bio/analytical chemistry, reproductive toxicology and inhalation toxicology. LAB Research also has the ability to perform GLP studies for regulatory submissions.
LAB Research has 450 employees including over 100 scientific professionals holding Ph.D., M.D. and M.Sc. degrees.
AccelLAB Inc.
www.accellab.com/index.html
CEO : Guy Leclerc, M.D.
VP Science: Louis-George Guy, Ph.D.
40 employees
AccelLAB is a non-clinical Contract Research Organization focused on large animal testing with a special focus in the field of interventional cardiology and regenerative medicine offering services from early drug or device development to late-stage non-clinical GLP studies.
AccelLAB offers its clients services in coronary stent development, drug-eluting stent studies, peripheral device development, cardiac cell transplant studies, etc.
Its team has been working together for over 5 years and is made of specialists such as veterinarians, animal health technicians, pathologists, and histology experts. This team is driven by Dr. Guy Leclerc, a lead interventional cardiologist from the University of Montreal Hospital.
Other Montreal-based companies play a significant role in the non-clinical research market such as ITR Laboratories (general toxicology, specialized infusion, inhalation toxicology, cardio profiling, etc.) or InSymbiosis (services in drug, biology, ADMET and chemistry discovery, etc.).
Companies in clinical contractual research
Montreal Metro has attracted some of the major CROs from the USA and Europe. These companies have operations in the region and have elected Montreal as the head for their Canadian operations.
Montreal has also been a very fertile soil for the creation of important local CROs with an international reputation.
It is estimated that one third of all beds available for phase I clinical studies in North America are located in the province of Quebec, most of them being in Montreal.
Quintiles Canada Inc.
www.quintiles.com
Director Global Sales: Martine Courtemanche
100 employees
Quintiles Transnational Corp., the world leader in CROs, has chosen Montreal as the head of its Canadian operations. With more than 100 employees, Quintiles Canada conducts clinical studies from phases II to phase IV and phase I/II studies in oncology. It offers a full range of services to pharmaceutical and biotech customers from Canada but also from the USA and abroad.
Quintiles Canada enjoys an excellent reputation in clinical studies and is pleased to benefit from an excellent network of clinicians and an easier access to patients in Canada and in Montreal in particular.
MDS Pharma Services Inc.
www.mdsps.com
Vice President and General Manager: Riaz Bandali
225 employees
MDS Pharma Services, a 35 year old Canadian company, is one of the largest and most respected global clinical research organizations in the world. It was ranked the top CRO in Europe in a survey of clinical investigators by Thompson CenterWatch in june 2006. It provides the largest capacity in early-phase clinical studies in the world.
The Montreal site specializes in early clinical development and offers a full range of services in Phase I/IIa and bioequivalence studies as well as comprehensive bioanalytical and PK/PD services. It also offers pharmacology and global clinical development services to its international client base. The Montreal site has an excellent track record for recruiting study participants thanks to the favourable environment in the Metro Montreal area and an access to special population of subjects.
Algorithme Pharma Inc.
www.algopharm.com
CEO : Louis Caillé
lcaille@algopharm.com
400 employees
Algorithme Pharma, another Canadian CRO, was founded 25 years ago in Montreal. It is a winner of the Canada’s 50 Best Managed Companies award.
Algorithme Pharma is a specialist of phase I and bioequivalence studies. It also runs a bioanalytical laboratory staffed with more than 90 people. Its clinical facilities include over 270 beds for phase I and bioequivalence studies. Algorithme Pharma prides itself of its unique access to a bank of volunteers of more than 52,000 potential study participants that includes special population segments and specific patient populations.
The company has been successfully audited by the North American, European and Brazilian regulatory authorities.
Cato Research Canada Inc.
www.cato.com
Regional Director: Michelle Frenette
60 employees
Established in Montreal in 1992, Cato Research Canada comprises 60 employees including a group of scientists who assist sponsors at all steps of the drug development process, and a team of experienced regional clinical research associates located in major Canadian cities.
Cato Research Canada offers a wide range of pharmaceutical development services, including nonclinical development strategy and toxicology study design, conduct and management; regulatory strategy, interactions with regulatory authorities and preparation of submissions; design, conduct and management of clinical studies (Phases I to IV); pharmacovigilance and medical monitoring; technical and medical writing; data management, statistical analysis and preparation of clinical study reports.
JSS Medical Research Inc.
www.jssresearch.com/home/
President: John S. Sampalis
45 employees
JSS Medical Research is a full scope integrated CRO that conducts phase II to IV clinical studies with proven expertise in post-marketing projects. The company was created in 1992 by Dr John S. Sampalis who is recognized as one of Canada's leading clinical epidemiologists, as well as the top trauma researcher in the country.
In a market where phase IV studies are now required to ascertain the true effectiveness and safety of a drug, the expertise of JSS Medical Research in clinical epidemiology and its scientific rigor have successfully helped its clients to address specific issues related to their marketed drugs. JSS Medical Research assists them from clinical study conception, protocol design to result dissemination in preparation of abstracts, conference material and peer reviewed published manuscript.
This document had been prepared by: Montréal International
Consultez notre groupe du LinkedIn